Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome


Bittner V. A., Szarek M., Aylward P. E., Bhatt D. L., Diaz R., Edelberg J. M., ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.75, sa.2, ss.133-144, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 75 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.jacc.2019.10.057
  • Dergi Adı: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.133-144
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).